Periodic Reporting for period 2 - MAGELIA (A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing)
Período documentado: 2020-08-01 hasta 2021-09-30
The MAGELIA project was born with the aim to fulfil the unmet needs in library preparation (DNA/RNA sample preparation) for low to medium throughput Next Generation Sequencing (NGS) analysis.
NGS is a set of powerful technologies that have enabled the reading of thousands to millions of DNA molecules simultaneously, revolutionizing fields such as personalised medicine, genetic diseases study, and clinical diagnostics. However, the upstream process to generate a collection of DNA fragments for reading, called library preparation, is still the main burden to NGS democratisation. For low-medium throughput laboratories, representing 80% of the market, NGS library preparation is currently done manually using several instruments and many manual steps like DNA amplification, pooling, normalisation, etc. This process is error-prone and leads to numerous pain-points for users such as large sample input required, low reproducibility, long hands-on-time and high cost.
At Inorevia, we believe that the solution to overcome these limitations lies in the miniaturisation and automation of library preparation by using our microfluidic technologies. To this end, we developed MAGELIA, a cutting-edge platform for low-medium throughput NGS library preparation.
MAGELIA will allow scarce-resources and small laboratories to use all NGS potential by reducing complexity and library preparation costs, increasing results’ reproducibility and freeing technicians’ time.
The H2020 SMEi2 project aims to transform a very promising platform prototype (TRL 6-7) to a fully automated, high quality and time-saving sample preparation instrument (TRL9). In parallel, all necessary actions strengthening the go-to-market strategy, communication & dissemination, and IP & FTO issues, will be implemented.
By the project ends, Inorevia achieved the full completion of the main milestones of the project, namely: the Magelia platform is ready to enter the Market, and applications have been developed to validate the potential of the platform.
The project will have a positive impact on the European biotech environment, and potentially trigger the emergence of European biotech leaders. Ultimately, through the improvement of Research and Diagnostics, it will benefit all European citizens.
NGS is a set of powerful technologies that have enabled the reading of thousands to millions of DNA molecules simultaneously, revolutionizing fields such as personalised medicine, genetic diseases study, and clinical diagnostics. However, the upstream process to generate a collection of DNA fragments for reading, called library preparation, is still the main burden to NGS democratisation. For low-medium throughput laboratories, representing 80% of the market, NGS library preparation is currently done manually using several instruments and many manual steps like DNA amplification, pooling, normalisation, etc. This process is error-prone and leads to numerous pain-points for users such as large sample input required, low reproducibility, long hands-on-time and high cost.
At Inorevia, we believe that the solution to overcome these limitations lies in the miniaturisation and automation of library preparation by using our microfluidic technologies. To this end, we developed MAGELIA, a cutting-edge platform for low-medium throughput NGS library preparation.
MAGELIA will allow scarce-resources and small laboratories to use all NGS potential by reducing complexity and library preparation costs, increasing results’ reproducibility and freeing technicians’ time.
The H2020 SMEi2 project aims to transform a very promising platform prototype (TRL 6-7) to a fully automated, high quality and time-saving sample preparation instrument (TRL9). In parallel, all necessary actions strengthening the go-to-market strategy, communication & dissemination, and IP & FTO issues, will be implemented.
By the project ends, Inorevia achieved the full completion of the main milestones of the project, namely: the Magelia platform is ready to enter the Market, and applications have been developed to validate the potential of the platform.
The project will have a positive impact on the European biotech environment, and potentially trigger the emergence of European biotech leaders. Ultimately, through the improvement of Research and Diagnostics, it will benefit all European citizens.
During the Magelia project, Inorevia developed and industrialized a fully-automated Lab Automation platform that tackles the challenges of small samples and volumes reduction.
The instrument is now commercialized and has been presented at a trade-show in Paris and a conference in London.
Several applications have been validated on the Magelia, with unprecedented results in Molecular Biology, that can be found at https://www.inorevia.com/applications
The instrument is now commercialized and has been presented at a trade-show in Paris and a conference in London.
Several applications have been validated on the Magelia, with unprecedented results in Molecular Biology, that can be found at https://www.inorevia.com/applications
Inorevia is promoting miniaturization and automation to better help Researchers in Biology reduce their time-to-results and costs. The Magelia platform is the only instrument capable of both miniaturization and automation of complex, multi-steps protocols, and will change the way molecular biology is performed in the lab, giving the lab more flexibility.
In the long term, Inorevia has the technologies and know how to become a European Leader in miniaturized solutions for the preparation of samples.
In the long term, Inorevia has the technologies and know how to become a European Leader in miniaturized solutions for the preparation of samples.